Chang Kuang-Yi, Ting Chien-Kun, Chan Kwok-Hon, Tsai Shen-Kou
Department of Anesthesiology, Taipei Veterans General Hsopital, Taipei, Taiwan, ROC.
Acta Anaesthesiol Taiwan. 2004 Dec;42(4):241-5.
Malignant hyperthermia (MH) is an operative emergency associated with general anesthesia. Early diagnosis and prompt treatment are the keynotes in management of MH. Dantrolene is the only specific drug and all of the institutions where general anesthesia is a daily routine should have a stockpile of this drug for the rare occurrence of MH. Nonetheless, the enormous expenditure on stockpile and 3-year validity make a large reserve of the drug to forestall MH, a disorder of rare occurrence, seems disputable, especially in small hospitals where general anesthesia is seldom practiced. We herein report two cases of MH with excellent response to small doses of dantrolene and then discuss the way of practicable management and debate on the question of whether fewer stock of dantrolene is an alternative way for hospitals of smaller scale.
恶性高热（MH）是一种与全身麻醉相关的手术急症。早期诊断和及时治疗是MH管理的关键。丹曲林是唯一的特效药物，所有日常进行全身麻醉的机构都应储备这种药物，以应对罕见的MH情况。然而，储备药物的巨大开支和3年的有效期使得大量储备该药以预防MH（一种罕见疾病）似乎存在争议，尤其是在很少进行全身麻醉的小医院。我们在此报告两例对小剂量丹曲林反应良好的MH病例，然后讨论可行的管理方法，并就减少丹曲林储备量是否是小规模医院的替代方法这一问题展开辩论。
